Mon, Jun 16, 8:16 PM (27 days ago)
**Zeo ScientifiX, Inc. (ZEOX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $1,149,000 (Q1 2025) vs. $1,131,000 (Q1 2024), a 1.6% increase. - **Gross Profit:** $893,000 (77.7% of revenue) in Q1 2025, up from $847,000 (74.9% of revenue) in Q1 2024. - **Net Loss:** $1,391,000 in Q1 2025, slightly improved from $1,399,000 in Q1 2024. - **Cash Flow:** Used $78,000 in operating activities in Q1 2025, significantly improved from $990,000 used in Q1 2024. **Profit Margins:** - Gross margin improved to 77.7% in Q1 2025 from 74.9% in Q1 2024. - Operating margin remained negative, reflecting high general and administrative expenses. **Cash Flow:** - Net cash used in operating activities decreased to $78,000 in Q1 2025 from $990,000 in Q1 2024. - Cash used in financing activities was $37,000 in Q1 2025, up from $20,000 in Q1 2024. **Earnings Changes:** - Net loss per share was $0.22 in Q1 2025, slightly improved from $0.23 in Q1 2024. **Quarterly Performance Discussion:** - Revenue growth was driven by increased sales of the PPX™ service platform, offset by decreased sales of allogenic aesthetic biologic products. - Gross profit increased due to higher margins from the PPX™ service platform. - General and administrative expenses decreased by 5.1%, primarily due to reduced payroll, consulting fees, and stock-based compensation costs. **Trends & Uncertainties:** - The company faces regulatory uncertainties regarding FDA guidelines for HCT/Ps. - Dependence on additional investment capital to fund operations and research. - Potential risks from ongoing litigation and legal proceedings. **Future Operations Impact:** - The company plans to continue clinical trials, expand international sales, and develop new product offerings. - Efforts to secure additional working capital through debt or equity financings. - Potential impact of FDA regulations on the company's ability to generate revenues. **Going Concern:** - The company has a stockholders' deficit of $2,100,000 as of April 30, 2025. - There is substantial doubt about the company's ability to continue as a going concern for the next 12 months. **Ticker:** ZEOX